419 related articles for article (PubMed ID: 32554615)
61. Cemiplimab for Locally Advanced Cutaneous Squamous Cell Carcinoma: A Case Series of 3 Unique Scenarios.
Akhtar K; Sravanthi MV; D'Angelo J; Sivapiragasam A
J Investig Med High Impact Case Rep; 2022; 10():23247096221121408. PubMed ID: 36017984
[TBL] [Abstract][Full Text] [Related]
62. A first-in-human, open-label, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity of QL1604, a humanized anti-PD-1 mAb, in patients with advanced or metastatic solid tumors.
Huang Z; Xu Y; Hong W; Gong L; Chen K; Qin J; Xie F; Wang F; Tian X; Meng X; Feng W; Li L; Zhang B; Kang X; Fan Y
Front Immunol; 2023; 14():1258573. PubMed ID: 37936687
[TBL] [Abstract][Full Text] [Related]
63. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
Rosenberg JE; Hoffman-Censits J; Powles T; van der Heijden MS; Balar AV; Necchi A; Dawson N; O'Donnell PH; Balmanoukian A; Loriot Y; Srinivas S; Retz MM; Grivas P; Joseph RW; Galsky MD; Fleming MT; Petrylak DP; Perez-Gracia JL; Burris HA; Castellano D; Canil C; Bellmunt J; Bajorin D; Nickles D; Bourgon R; Frampton GM; Cui N; Mariathasan S; Abidoye O; Fine GD; Dreicer R
Lancet; 2016 May; 387(10031):1909-20. PubMed ID: 26952546
[TBL] [Abstract][Full Text] [Related]
64. A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLC.
Wang L; Luo Y; Ren S; Zhang Z; Xiong A; Su C; Zhou J; Yu X; Hu Y; Zhang X; Dong X; Meng S; Wu F; Hou X; Dai Y; Song W; Li B; Wang ZM; Xia Y; Zhou C
J Thorac Oncol; 2024 Mar; 19(3):465-475. PubMed ID: 37879536
[TBL] [Abstract][Full Text] [Related]
65. Survival with Cemiplimab in Recurrent Cervical Cancer.
Tewari KS; Monk BJ; Vergote I; Miller A; de Melo AC; Kim HS; Kim YM; Lisyanskaya A; Samouëlian V; Lorusso D; Damian F; Chang CL; Gotovkin EA; Takahashi S; Ramone D; Pikiel J; Maćkowiak-Matejczyk B; Guerra Alía EM; Colombo N; Makarova Y; Rischin D; Lheureux S; Hasegawa K; Fujiwara K; Li J; Jamil S; Jankovic V; Chen CI; Seebach F; Weinreich DM; Yancopoulos GD; Lowy I; Mathias M; Fury MG; Oaknin A;
N Engl J Med; 2022 Feb; 386(6):544-555. PubMed ID: 35139273
[TBL] [Abstract][Full Text] [Related]
66. Immune checkpoint inhibitors in advanced cutaneous squamous cell carcinoma: A systemic review and meta-analysis.
Zhang H; Zhong A; Chen J
Skin Res Technol; 2023 Jan; 29(1):e13229. PubMed ID: 36329570
[TBL] [Abstract][Full Text] [Related]
67. First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies.
Papadopoulos KP; Johnson ML; Lockhart AC; Moore K; Falchook GS; Formenti SC; Naing A; Carvajal RD; Rosen LS; Weiss GJ; Leidner RS; Li J; Paccaly A; Feng M; Stankevich E; Lowy I; Fury MG; Crittenden MR
Clin Cancer Res; 2020 Mar; 26(5):1025-1033. PubMed ID: 31796520
[TBL] [Abstract][Full Text] [Related]
68. Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.
Jabbour SK; Berman AT; Decker RH; Lin Y; Feigenberg SJ; Gettinger SN; Aggarwal C; Langer CJ; Simone CB; Bradley JD; Aisner J; Malhotra J
JAMA Oncol; 2020 Jun; 6(6):848-855. PubMed ID: 32077891
[TBL] [Abstract][Full Text] [Related]
69. Population pharmacokinetics modeling and exposure-response analyses of cemiplimab in patients with recurrent or metastatic cervical cancer.
Nguyen JH; Epling D; Dolphin N; Paccaly A; Conrado D; Davis JD; Al-Huniti N
CPT Pharmacometrics Syst Pharmacol; 2022 Nov; 11(11):1458-1471. PubMed ID: 36251220
[TBL] [Abstract][Full Text] [Related]
70. Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab.
Hamid O; Molinero L; Bolen CR; Sosman JA; Muñoz-Couselo E; Kluger HM; McDermott DF; Powderly JD; Sarkar I; Ballinger M; Fassò M; O'Hear C; Chen DS; Hegde PS; Hodi FS
Clin Cancer Res; 2019 Oct; 25(20):6061-6072. PubMed ID: 31358540
[TBL] [Abstract][Full Text] [Related]
71. Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial.
Xie L; Xu J; Sun X; Guo W; Gu J; Liu K; Zheng B; Ren T; Huang Y; Tang X; Yan T; Yang R; Sun K; Shen D; Li Y
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32376724
[TBL] [Abstract][Full Text] [Related]
72. PD-1 inhibitors for cutaneous squamous cell carcinoma: A meta-analysis.
Aboul-Fettouh N; Chen L; Ma J; Patel J; Silapunt S; Migden M
Australas J Dermatol; 2022 Feb; 63(1):36-42. PubMed ID: 34699068
[TBL] [Abstract][Full Text] [Related]
73. Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study.
Ott PA; Elez E; Hiret S; Kim DW; Morosky A; Saraf S; Piperdi B; Mehnert JM
J Clin Oncol; 2017 Dec; 35(34):3823-3829. PubMed ID: 28813164
[TBL] [Abstract][Full Text] [Related]
74. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
Hamid O; Robert C; Daud A; Hodi FS; Hwu WJ; Kefford R; Wolchok JD; Hersey P; Joseph RW; Weber JS; Dronca R; Gangadhar TC; Patnaik A; Zarour H; Joshua AM; Gergich K; Elassaiss-Schaap J; Algazi A; Mateus C; Boasberg P; Tumeh PC; Chmielowski B; Ebbinghaus SW; Li XN; Kang SP; Ribas A
N Engl J Med; 2013 Jul; 369(2):134-44. PubMed ID: 23724846
[TBL] [Abstract][Full Text] [Related]
75. Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study.
Mehnert JM; Bergsland E; O'Neil BH; Santoro A; Schellens JHM; Cohen RB; Doi T; Ott PA; Pishvaian MJ; Puzanov I; Aung KL; Hsu C; Le Tourneau C; Hollebecque A; Élez E; Tamura K; Gould M; Yang P; Stein K; Piha-Paul SA
Cancer; 2020 Jul; 126(13):3021-3030. PubMed ID: 32320048
[TBL] [Abstract][Full Text] [Related]
76. Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase II Trial.
Ferrarotto R; Sousa LG; Qing Y; Kaya D; Stephen B; Jain D; Bell D; Pant S; Tsimberidou AM; Janku F; Blumenschein G; Glisson BS; Ahnert JR; Piha-Paul SA; Lee JJ; Wong MK; Lu C; Meric-Bernstam F; Naing A
Adv Ther; 2021 Aug; 38(8):4581-4591. PubMed ID: 34241781
[TBL] [Abstract][Full Text] [Related]
77. Neoadjuvant-Intent Immunotherapy in Advanced, Resectable Cutaneous Squamous Cell Carcinoma.
Kim EY; Ruiz ES; DeSimone MS; Shalhout SZ; Hanna GJ; Miller DM; Schmults C; Rettig EM; Foreman RK; Sethi R; Thakuria M; Silk AW
JAMA Otolaryngol Head Neck Surg; 2024 May; 150(5):414-420. PubMed ID: 38546619
[TBL] [Abstract][Full Text] [Related]
78. Prolonged Response to Pembrolizumab in Spindle Cell Squamous Cell Carcinoma Metastatic to the Central Nervous System.
Liu Y; Fitzgerald B; Perry E; Pathak A; Chao HH
J Investig Med High Impact Case Rep; 2019; 7():2324709619850216. PubMed ID: 31132886
[TBL] [Abstract][Full Text] [Related]
79. Immune checkpoint blockade with anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) cemiplimab: ongoing and future perspectives in rare genital cancers treatment.
Gambale E; Fancelli S; Caliman E; Petrella MC; Doni L; Pillozzi S; Antonuzzo L
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101944
[TBL] [Abstract][Full Text] [Related]
80. Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02).
Wang FH; Wei XL; Feng J; Li Q; Xu N; Hu XC; Liao W; Jiang Y; Lin XY; Zhang QY; Yuan XL; Huang HX; Chen Y; Dai GH; Shi JH; Shen L; Yang SJ; Shu YQ; Liu YP; Wang W; Wu H; Feng H; Yao S; Xu RH
J Clin Oncol; 2021 Mar; 39(7):704-712. PubMed ID: 33492986
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]